Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families.

Like Comment
Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult to treat form of skin cancer until the hedgehog inhibitor (HHI) vismodegib was approved. Approximately 80% of laBCCs occur in the head and neck region causing disfiguring skin changes that impact on patients' quality of life. Because the lives of patients with advanced BCCs are severely disrupted, it would be expected that the quality of life of family members involved in caregiving, would also be affected. The aim of our study was to quantify the quality of life (QoL) of both patients and family members during vismodegib treatment using the Dermatology Life Quality Index and the Family Dermatology Life Quality Index questionnaire, respectively.


Click here to read the full article @ Clinical and experimental dermatology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
1 Followers
0 Following

No comments yet.